IRCT20221025056289N1 IRCT 2023-04-17 Alborz University of Medical Science the effect of citalopram on negative symptoms of schizophrenia The effect of citalopram as an adjunctive therapy with olanzapine or aripiprazole on the improvement of negative symptoms in patients with chronic schizophrenia in placebo - randomized clinical trial 2023-04-25 anticipated 160 Complete https://irct.ir/trial/66694 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Individual randomization will be performed using a four-block randomization scheme. The random sequence will be generated using STATA software and random numbers. In addition, to ensure randomization concealment, opaque, sealed envelopes will be used, which will be marked with a 5-digit random number sequence, Blinding description: In this study, the patients and the therapist will be blinded to the randomization assignment (double-blind). 3 Schizophrenia. Intervention 1: Intervention group: Under treatment with citalopram (up to 40 milligrams per day) and olanzapine (dose of 15 milligrams). Intervention 2: Intervention group: Under treatment with Citalopram (maximum of 40 milligrams per day) in addition to Aripiprazole (20 milligrams per day). Intervention 3: Control group: Under treatment with 15 milligrams per day of olanzapine accompanied by medication schedule. Intervention 4: Control group: Under treatment with Aripiprazole, 15 to 20 milligrams per day, accompanied by medication schedule. No - There is not a plan to make this available Justification or reason for not sharing IPD is The data won't be released until the publication of the study.